Larotrectinib Elicits Early Clinical Activity in NTRK Fusion–Positive Lung Cancer
February 2nd 2021
February 2, 2021 — Larotrectinib was found to elicit high response rates, durable responses, and to extend survival benefit in patients with advanced lung cancer whose tumors harbor an NTRK gene fusion, including those with central nervous system metastases.